New hope for Hard-to-Treat breast cancer: drug combo trial launches
NCT ID NCT07354022
First seen Jan 26, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This phase 3 trial tests whether a new drug (HRS-8080) combined with dalpiciclib works better than a standard drug (fulvestrant) combined with dalpiciclib for people with advanced breast cancer that no longer responds to hormone therapy. About 912 women aged 18-75 with locally advanced or metastatic breast cancer will participate. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital Fifth Medical Center
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact
Conditions
Explore the condition pages connected to this study.